Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Dr Reddy’s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India.
Dr Reddy’s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19.
“The need for high efficacy and quality, affordability and improved disease control are essential priorities for us. We think that Avigan would offer an effective treatment alternative to the COVID-19 affected sufferers in India,” M Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, stated.
